Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating Scale

Simple item page
dc.contributor.authorBadrising, U.A.
dc.contributor.authorHenderson, R.
dc.contributor.authorReddel, S.
dc.contributor.authorCorbett, A.
dc.contributor.authorLiang, C.
dc.contributor.authorReardon, K.
dc.contributor.authorGhaoui, R.
dc.contributor.authorBulsara, M.
dc.contributor.authorBrady, S.
dc.contributor.authorBrusch, A.
dc.contributor.authorChan, D.
dc.contributor.authorCoudert, J.D.
dc.contributor.authorFairchild, T.
dc.contributor.authorJain, G.
dc.contributor.authorKiernan, M.C.
dc.contributor.authorLeonard, D.
dc.contributor.authorLloyd, T.
dc.contributor.authorSchmidt, J.
dc.contributor.authorMcDermot, M.P.
dc.contributor.authorSanders, L.
dc.contributor.authoret al.
dc.date.issued2025
dc.description.abstractOBJECTIVES: Inclusion body myositis (IBM) is a complex inflammatory muscle disease in adults over 40, with histological features of autoinflammation, cell stress and autophagic abnormalities, and marked clinically by relentless progression with no effective disease-modifying therapy. Sirolimus (rapamycin) may help maintain function by inhibiting T effector cells, preserving T regulatory cells, inducing autophagy, and improving mitochondrial function. This international trial follows a phase II pilot study. METHODS: This phase IIb/III double-blind, randomised, controlled trial (RCT) of sirolimus involves 140 IBM patients randomly assigned with equal allocation to sirolimus (2 mg) or matching placebo. This RCT aims to assess the efficacy of sirolimus compared to placebo in slowing or stabilising IBM progression, as measured by the mean change in patient function using the IBM Functional Rating Scale (IBM-FRS) from Baseline to Week 84. Secondary outcomes will evaluate efficacy and safety to inform future clinical trial design. RESULTS: Ethical approval has been granted in Australia (St Vincent’s Hospital Melbourne HREC-D 311/20) and the USA (University of Kansas Medical Center Human Research Protection Program FWA no. 00003411), with European approval pending. The protocol is version 3.0 (02-Dec-2022). Trial registration: ANZCTR: ACTRN12620001226998p, ClinicalTrials.gov: NCT04789070, UTN: U1111-1258-1354, and EU CT 2024-514575-17-00. CONCLUSIONS: This phase IIb/III trial builds on prior findings to assess sirolimus’s potential in slowing or halting IBM progression, preserving patient function and independence, and advancing IBM therapeutic strategies and trial design.
dc.description.statementofresponsibilityU.A. Badrising, R. Henderson, S. Reddel, A. Corbett, C. Liang, K. Reardon, R. Ghaoui, M. Bulsara, S. Brady, A. Brusch, D. Chan, J.D. Coudert, T. Fairchild, G. Jain, M.C. Kiernan, D. Leonard, T. Lloyd, J. Schmidt, M.P. McDermott, L. Sanders, C. Lowe, A.J. van der Kooi, C. Weihl, P. Mohassel, M. Simpson, A. Carroll, I. Cooper, K. Beer, K. Hiscock, S. Walters, A. Panicker, A. Doverty, A.J. Heim, M. van Heur-Neuman, O. Benveniste, M.M. Dimachkie, M. Needham
dc.identifier.citationClinical and Experimental Rheumatology, 2025; 43(2):316-325
dc.identifier.doi10.55563/clinexprheumatol/zvffa0
dc.identifier.issn0392-856X
dc.identifier.issn1593-098X
dc.identifier.orcidGhaoui, R. [0000-0003-2309-2086]
dc.identifier.urihttps://hdl.handle.net/2440/146006
dc.language.isoen
dc.publisherClinical and Experimental Rheumatology
dc.relation.grantNHMRC
dc.rights© Copyright Clinical and Experimental Rheumatology 2025.
dc.source.urihttps://doi.org/10.55563/clinexprheumatol/zvffa0
dc.subjectClinical Trials, Phase II as Topic
dc.subjectClinical Trials, Phase III as Topic
dc.subjectDisease Progression
dc.subjectDouble-Blind Method
dc.subjectImmunosuppressive Agents
dc.subjectMyositis, Inclusion Body
dc.subjectRandomized Controlled Trials as Topic
dc.subjectSirolimus
dc.subjectTreatment Outcome
dc.subjectclinical trials; inclusion body myositis; international; investigator-inititated
dc.titleOptimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating Scale
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Research Outputs